#United States #StimLabs #Vizient #Roswell #Regenerative Biologics

StimLabs Secures a Major Contract with Vizient

StimLabs, a leader in regenerative science, has recently announced a significant milestone in its growth trajectory. As of August 1, 2025, the company has been awarded a national contract with Vizient, a notable healthcare performance improvement company. This partnership is set to open new doors for hospitals across the United States, providing them with access to StimLabs’ advanced regenerative biologics at preferential pricing and improved terms.

The Importance of the Contract

This agreement allows the Vizient network—which encompasses over 3,500 hospitals, including 97% of academic medical centers—to benefit from StimLabs’ cutting-edge regenerative products. John Daniel, the Founder and CEO of StimLabs, emphasized the vital nature of this contract, stating, "Our purpose has always been to transform lives through regenerative science. With this agreement, we have significantly expanded our reach and are well positioned to make a larger impact on patient care at the hospital site of service."

StimLabs' Innovative Product Portfolio

StimLabs has consistently led in innovation within the regenerative medicine field. The company's history includes the commercialization of the first-ever full-thickness, intact placental membrane allograft developed with their proprietary Clearify® technology in 2016. More recently, in 2024, they introduced Corplex P®, the first FDA 510(k)-cleared medical device made from umbilical cord-derived tissue.

Tom Dion, Executive Vice President and Chief Commercial Officer, stated, "We continue to execute on our strategy to strengthen our presence in the acute care space. This agreement with Vizient marks another important milestone for us. Through it, we have secured access to over 65% of the nation's acute care providers. This achievement broadens our capacity to serve more patients with our diverse product line, including our latest innovation, Corplex P."

About StimLabs

Founded in 2015, StimLabs has aimed to innovate with a purpose, transforming lives through regenerative science. With a team of industry leaders, the company is focused on delivering top-quality regenerative solutions while addressing critical clinical needs. StimLabs boasts a comprehensive product portfolio that caters to a variety of medical applications, backed by a robust intellectual property catalog. Their commitment to quality positions them as a trusted partner for both healthcare providers and patients.

About Vizient

Vizient is recognized for its ability to provide insightful analytics derived from vast clinical, operational, and supply chain data. Their mission is to empower healthcare organizations to optimize care delivery while maintaining cost-effectiveness across operations.

In conclusion, the partnership between StimLabs and Vizient paves the way for improved healthcare services across the nation, making significant strides in patient care and advancing regenerative medicine practices on a broader scale.

For further details on StimLabs and their innovative products, visit www.stimlabs.com.